Dr. Jay Yang, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 186
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Michigan Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301084642 -
Internal Medicine Physician
MI license 4301084642
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Harper University Hospital Detroit, MI
- Karmanos Cancer Center Detroit, MI
Medical groups
- University Physician Group (403 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 186
- Services billed
- 601
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 305 | 105 |
| Established patient office or other outpatient visit, 20-29 minutes | 58 | 50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 46 | 12 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 90 |
| Acyclovir Other prescribers in Detroit, MI | 29 |
| Venclexta (venetoclax) | 19 |
| Xospata (gilteritinib fumarate) | 19 |
| Hydroxyurea Other prescribers in Detroit, MI | 18 |
| Ondansetron Hcl Other prescribers in Detroit, MI | 15 |
| Bosulif (bosutinib) | 15 |
| Allopurinol Other prescribers in Detroit, MI | 13 |
| Ciprofloxacin Hcl Other prescribers in Detroit, MI | 13 |
| Iclusig (ponatinib hcl) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $54.85 in total to this clinician.
| Kite Pharma, Inc. | $31.75 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $23.10 |
| Food and Beverage | $31.75 |
|---|---|
| Education | $23.10 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP May 21, 2025 | Education in-kind Company’s descriptionJournal Article | $23.10 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $97,567 in research payments for these studies, mostly to the institutions running them.
- A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia
Janssen Research & Development, LLC - A phase 1 study of SEACD70 in myeloid malignancies
Pfizer Inc. - A phase 1 study of SGNPDL1V in advanced solid tumors
Pfizer Inc. - A phase 1 openlabel study to evaluate SGN35C in adults with advanced malignancies
Pfizer Inc. - Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
Novartis Pharmaceuticals Corporation - A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Janssen Research & Development, LLC - A phase 1 study of SGNEGFRD2 in advanced solid tumors
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.